ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organisation, today releases its ICON Cares 2025 Report which outlines how the company is delivering on its...
ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, today announced the pricing by its wholly-owned subsidiary, ICON Investments Six Designated Activity Company...
ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the “Issuer”),...
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 31,...
Highlights Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. Quarter two adjusted EBITDA of $327.2 million or 15.9%...
Barchart Research What to Expect from ICLR Earnings ICLR Generated July 28, 2026 Current Price $180.24 EPS Estimate $$2.26 Consensus Rating Moderate Buy Average Move 10.66% ICLR Reports Tomorrow After...
ICON plc (NASDAQ: ICLR) today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON’s digital...
ICON plc , (NASDAQ: ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the second quarter 2026 after the market...
Barchart Research What to Expect from ICLR Earnings ICLR Generated July 21, 2026 Current Price $166.62 EPS Estimate $$2.26 Consensus Rating Moderate Buy Average Move 10.66% ICON's Lab Expansion Looks Confident...